سوفوسبوفير
| Kind | API |
|---|---|
| Class | Antiviral — HCV NS5B polymerase inhibitor (nucleotide prodrug) |
| Synonyms | SOF, GS-7977, PSI-7977, Sovaldi |
| Common uses / forms | Oral tablets for chronic hepatitis C; fixed-dose combinations with daclatasvir, ledipasvir or velpatasvir |
| Properties | BCS Class III (high solubility, low permeability); phosphoramidate prodrug with multiple stereocentres; polymorphic so solid-form control is required |
| Compendia | USP, IP |
| Sourcing origins | India, China |
| Dominant inbound route | Hormuz |
| Indicative price band | $$$ ($100–1000 / kg) |
| Indicative lead time | medium (50–80 days) |
| Notes | Demanding multi-chiral prodrug synthesis and impurity control; Gilead voluntary-licence generic supply from India (Egypt also a major maker); polymorph control critical; EP/BP not claimed (recent molecule) |
Open the interactive Data Bank (363 substances) · the full table · Supply Resilience Studio
Share: LinkedIn · X · WhatsApp · Telegram · Email
Cite as: AUPAM Experts' Office, Sofosbuvir — sourcing profile (API) — AUPAM Data Bank, retrieved 2026-08-31, https://aupameo.org/datasets/databank/a-sofosbuvir.html